Sugi Predict

Sugi Predict / Targets / UGT8

UGT8

2-hydroxyacylsphingosine 1-beta-galactosyltransferase · Q16880 · UGT8 on Sugi Atlas →

1,287 patent compounds predicted against UGT8, 939 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21813564 SCHEMBL21813564 1.00 20/20
SCHEMBL21813697 SCHEMBL21813697 1.00 20/20
SCHEMBL21813791 SCHEMBL21813791 1.00 20/20
SCHEMBL21813887 SCHEMBL21813887 1.00 20/20
SCHEMBL21814089 SCHEMBL21814089 1.00 20/20
SCHEMBL21814111 SCHEMBL21814111 1.00 20/20
SCHEMBL21813999 SCHEMBL21813999 0.95 20/20
SCHEMBL21813781 SCHEMBL21813781 0.89 20/20
SCHEMBL21813358 SCHEMBL21813358 0.89 20/20
SCHEMBL21813755 SCHEMBL21813755 0.88 20/20
SCHEMBL21813758 SCHEMBL21813758 0.88 20/20
SCHEMBL21813783 SCHEMBL21813783 0.88 20/20
SCHEMBL21814017 SCHEMBL21814017 0.88 20/20
SCHEMBL21813881 SCHEMBL21813881 0.86 20/20
SCHEMBL21813663 SCHEMBL21813663 0.85 20/20
SCHEMBL21813665 SCHEMBL21813665 0.85 20/20
SCHEMBL21813703 SCHEMBL21813703 0.85 20/20
SCHEMBL21813857 SCHEMBL21813857 0.85 20/20
SCHEMBL21813591 SCHEMBL21813591 0.85 20/20
SCHEMBL21813413 SCHEMBL21813413 0.83 20/20

Clinical trials — most relevant to UGT8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity PHASE4COMPLETED
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes PHASE4NOT_YET_RECRUITING
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
The Role of SGLT2i in Management of Moderate AS PHASE2/PHASE3UNKNOWN
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
CBD for Pain Following Orthopedic Shoulder Surgery PHASE1/PHASE2RECRUITING
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 PHASE2RECRUITING
A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency PHASE2COMPLETED
The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) PHASE1/PHASE2COMPLETED
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy PHASE2COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease PHASE2COMPLETED
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease PHASE1/PHASE2UNKNOWN
Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia PHASE1/PHASE2COMPLETED
GM1 Ganglioside Effects on Parkinson's Disease PHASE2COMPLETED
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours PHASE1UNKNOWN
A Study of GLB-001 in Patients With Myeloid Malignancies PHASE1RECRUITING
Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects PHASE1COMPLETED
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. PHASE1RECRUITING
XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers PHASE1COMPLETED
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin PHASE1COMPLETED
Study of NK012 in Patients With Refractory Solid Tumors PHASE1COMPLETED
Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment PHASE1COMPLETED
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers PHASE1COMPLETED
Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects PHASE1COMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Natural History Study of Participants With Sanfilippo Syndrome Type IIIC nanRECRUITING
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform. nanUNKNOWN
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a UGT8 binder may also engage these)

ProteinNameSimilarity
Q09426 — 1.000 Q09426 →
Q64676 — 1.000 Q64676 →
Q63ZR6 — 0.994 Q63ZR6 →
P34317 — 0.992 P34317 →
Q8JZZ0 — 0.992 Q8JZZ0 →
Q10941 — 0.990 Q10941 →
Q1LZI1 — 0.989 Q1LZI1 →
Q6NUS8 — 0.988 Q6NUS8 →
Q20086 — 0.987 Q20086 →
A0A291PQF1 — 0.987 A0A291PQF1 →
Q3SY77 — 0.987 Q3SY77 →
Q18081 — 0.987 Q18081 →
A8WLF6 — 0.986 A8WLF6 →
Q62789 — 0.985 Q62789 →
A0A291PQG3 — 0.985 A0A291PQG3 →
A0A291PQH4 — 0.984 A0A291PQH4 →
P08541 — 0.984 P08541 →
Q21706 — 0.984 Q21706 →
Q3UP75 — 0.984 Q3UP75 →
Q22295 — 0.984 Q22295 →
P19488 — 0.983 P19488 →
Q5RFJ3 — 0.983 Q5RFJ3 →
P09875 — 0.983 P09875 →
Q83140 — 0.983 Q83140 →
O19103 — 0.983 O19103 →
Q6UWM9 — 0.982 Q6UWM9 →
Q98166 — 0.981 Q98166 →
Q22181 — 0.981 Q22181 →
P36511 — 0.980 P36511 →
Q88168 — 0.980 Q88168 →